Keratoacanthoma
☆ AI Dermatology — Free Service
I te 2022 Stiftung Warentest hua mai i Tiamana, he iti noa iho te pai o nga kaihoko ki a ModelDerm i nga korero mo te waea rongoa utu.
I te 2022 Stiftung Warentest hua mai i Tiamana, he iti noa iho te pai o nga kaihoko ki a ModelDerm i nga korero mo te waea rongoa utu.
Keratoacanthoma (Keratoacanthoma)
relevance score : -100.0%
ReferencesKo te Keratoacanthoma (KA) he pukupuku kiri auau, he pāwera iti (kāore e tino whakawhānui, kāore e hēke), ā, ka tipu tere, ā, e whakapono ana he tīmata i te pūpū kiri. Ka taea te āhua o te pūkete ki te rite ki te squamous cell carcinoma (kanaseru pūkete squamous). Ka kitea te nuinga o ngā wā i te kiri kua pā ki te rā, pērā i te kanohi, ngā ringa o mua, me ngā ringa.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Ko te Keratoacanthoma (KA) he puku iti‑koeke ka timata i roto i etahi repe o te kiri ka rite te ahua ki te squamous cell carcinoma (SCC) i te āhua. Kei te haere tonu nga tautohetohe mo te mea me whakarōpūhia a KA hei momo SCC urutomo.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Ko Cutaneous squamous cell carcinoma (cSCC) te tuarua o nga momo mate pukupuku e tino kitea ana i roto i nga tangata, ina koa i waenga i nga taangata pakeke. I te nuinga o te wa ka whakamahia te pokanga ki te rongoa cSCC, engari mo etahi o nga turoro kaore e taea te mahi pokanga, ka kore ranei e pai, ka taea te whakaaro ki etahi atu momo rongoa penei i nga maimoatanga intralesional. Kua whakamahia nga rongoa tuku iho (methotrexate or 5-fluorouracil), engari kei te haere tonu te rangahau mo nga huarahi hou penei i te imunoterapi intralesional (intralesional immunotherapy) me te viroterapi oncolytic (oncolytic virotherapy). I konei, ka titiro tatou ki nga momo maimoatanga intralesional mo cSCC, mai i nga tikanga matarohia ki nga rautaki tapahi.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
I raro i te karu, ko keratoacanthoma he rite tonu te ahua o te squamous cell carcinoma. Ahakoa ka whakarōpūhia e ētahi tohunga pathotanga te keratoacanthoma he hinonga motuhake, ehara i te mate kino, tata ki te 6 % o ngā keratoacanthoma haumanu me te hitori e ahu whakamua ana ki te squamous cell carcinoma.
○ Taatari me te Maimoatanga
#Dermoscopy
#Skin biopsy